Ozempic & GLP-1 Lawsuit in Florida

GLP-1 receptor agonist medications — including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, and Trulicity — were prescribed to millions of Florida residents for type 2 diabetes and weight management. While these drugs were marketed as breakthrough treatments, growing evidence has linked them to severe and sometimes permanent injuries that the manufacturers allegedly failed to adequately disclose.

The federal litigation against Novo Nordisk and Eli Lilly has been consolidated into multidistrict litigation (MDL 3094) in the Eastern District of Pennsylvania. Florida residents who suffered injuries from GLP-1 medications can file claims that join this consolidated proceeding, benefiting from coordinated pretrial discovery while retaining their individual right to trial.

The lawsuits allege that the manufacturers knew their drugs could cause serious gastrointestinal injuries — including stomach paralysis, bowel blockages, and pancreatic inflammation — as well as vision loss, yet they prioritized profits over patient safety by failing to warn prescribers and patients about the true scope of these risks. For Florida residents, the stakes are high: these injuries can be permanent, require multiple surgeries, and fundamentally alter quality of life.

As the litigation progresses, early bellwether trials are expected to set the stage for broader settlement discussions. Florida residents who have been injured should evaluate their claims now, before filing deadlines expire.

Florida legal landscape: Florida reformed its tort laws significantly in 2023, adopting a modified comparative fault system with a 51% bar. The state applies strict liability for manufacturing defects but uses a negligence standard for design defect claims, and it recognizes the learned intermediary doctrine. Residents in Miami, Tampa, Orlando, Jacksonville, and Fort Lauderdale and surrounding areas should consult with an attorney experienced in pharmaceutical litigation to evaluate their potential claim.